SenzaGen AB reported consolidated sales results for the first quarter of 2023. Consolidated net sales in the January- March period increased by 36% to SEK 12.3 million driven by strong GARD® sales from new and returning major global customers combined with growth in VitroScreen's innovation services for medical devices, cosmetics and pharmaceuticals.